Context Therapeutics Inc.
NASDAQContext Therapeutics heads into its May 8 earnings call having already reported Q1 numbers — and the initial read is a beat. The EPS surprise is the headline. Q1 EPS came in at $(0.09), topping the $(0.12) estimate. That lands in context of a factor score that already ranks CNTX in the 79th percentile for EPS surprise — the company has form here. With the result out early evening…
Snapshot as of 7 May 2026
Context Therapeutics heads into its May 8 earnings call having already reported Q1 numbers — and the initial read is a beat. The EPS surprise is the headline. Q1 EPS came in at $(0.09), topping the $(0.12) estimate.…
Context Therapeutics enters its Q1 2026 earnings release with short sellers having already made a decisive exit — and Q1 EPS just printed a beat, coming in at -$0.09 versus the -$0.12 estimate. Short interest has…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CNTX — free to start on ORTEX.
Sign up for free →Open CNTX on ORTEX